RE:Links to the two Posters are below I already said, great science! Still the disconnect between preclinical and clinical is baffling and frustrating. I'm really seeing the homogeneity of SORT expression in those xenografts and wondering if that's the difference or for some reason is this drug just not finding it's way into the human tumours? The science looks sound to me.
I think the STING paper is maybe where this goes if the monotherapy fails to meet expectations given it is the clearest pointer towards combo therapy. But if the plan is to get a partner who has a PDC-1 drug AND the cash AND the willingness to test it with an experimental drug that failed to hit endpoints in a Ph1 then it looks like a tough ask (to put it mildly).
Let's hope for a (some) responders!
Mannequin wrote: There is a link to the two results. Anyone care to share their thoughts.
1: https://www.theratech.com/static-files/1a9f26d3-36a4-4a88-8e36-d2f181b1d106
2: https://www.theratech.com/static-files/0be9328a-7bdf-4f07-abd7-9c678dca4a2a